Eli Lilly and Co said on Friday the U.S. health regulator approved its drug for the treatment of a rare form of blood cancer. The wholesale cost of the treatment, Jaypirca, will be $21,000 per 30 days for the 200 mg dose, the U.S. drugmaker told Reuters.